Jaime Rosenberg

November 29, 2021

In a recent study, researchers detailed the use of various biosensors for minimal residual disease (MRD) detection in non–small cell lung cancer (NSCLC).

November 24, 2021

The recommendations come at a time when treatments for chronic lymphocytic leukemia (CLL), such as venetoclax, are making deep remissions and undetectable minimal residual disease (MRD) after a fixed duration of treatment feasible goals.

November 24, 2021

The data set included 177 samples from polycythemia vera, essential thrombocytopenia, primary myelofibrosis, and healthy donors, from which the researchers found that MAPK14 was overexpressed in PV samples and was associated with more symptoms and worse outcomes.

November 19, 2021

The approach works by transforming the condition of normal and tumor cells into a highly proliferative “reprogrammed stem-like” condition that still has the original karyotypes.

November 17, 2021

The findings showed that between 2009 to 2016, 76% of the 122 patients included in the study were on sick leave a year following their allogeneic hematopoietic stem cell transplantation (allo-HSCT).

November 13, 2021

The drug sensitivity test-guided treatment was associated with significant improvements in the patient’s condition after 8 weeks.

November 13, 2021

According to the study authors, a growing number of findings from preclinical studies have suggested a focus on immunometabolism to modulate alloreactive donor T cell responses to control graft-versus-host disease (GVHD) and promote graft-versus-tumor effect.

November 12, 2021

To date, just 3 previous reports have detailed cases of mitochondrial malate dehydrogenase deficiency (MDH2D), and there are no known cures.

November 11, 2021

Across all studies included, observed-to-expected ratios showed that White and Asian patients were overrepresented while Black patients, Hispanic patients, and American Indian/Alaskan Native patients were underrepresented.

September 29, 2021

These second-generation inhibitors include acalabrutinib, zanubrutinib, and tirabrutinib, and researchers hope they can overcome the off-target toxicity and treatment resistance that can be experienced with ibrutinib.